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ABSTRACT: Ganoderma lucidum has been hailed as medicinal mushroom. Its effect on memory and 
learning related behavioral performance along with related protein markers has been evaluated using 
Alzheimer’s disease (AD) and hypercholesterolemic model rats in the present study. AD model rats were 
prepared infusing amyloid beta peptide into the right ventricles of the rats. Hypercholesterolemia was evoked 
feeding 1% cholesterol and 1% cholic acid with basal diet of the rats for 8 weeks. Hot water extract of          
G. lucidum was ingested orally (200 mg/kg bw) to the HC and AD model rats. Memory and learning related 
behavioral tests were performed using Barnes maze while protein markers (BDNF, SNAP2, PSD-95, VAchT) 
were detected using ELISA. Observed findings suggest hypocholesterolemic, lipid profile improving and 
enhanced cognitive performance of the G. lucidum fed rats. Memory and learning related protein markers also 
substantiate this fruition. Thus, therapeutic potentiality of Ganoderma lucidum in AD amelioration seems 
promising. 
Keywords: Alzheimer’s disease; Ganoderma lucidum; Hypercholesterolemia; Memory and learning; Protein 
markers of memory and learning. 
1. INTRODUCTION 
Alzheimer’s disease (AD), a neuro-degenerative disorder affects memory and learning abilities and 
induces behavioral disorder especially in the elderly people [1]. Neurons and neurotransmitters associated 
with memory, learning and behavioral normalcy become disrupted in the AD patients [1]. Deposition of 
amyloid beta (Aβ) plaques and/or neurofibrillary tangles (NFTs) in the AD neurons impairs their usual 
activities [2]. Consequently, AD patients become solely dependent on their family members and care givers 
and add extra burden as well as negative impact on national and global economy [3,4]. Unfortunately, there is 
hardly any treatment for more than 40 million AD patients suffering globally [5]. Current COVID-19 
epidemic has lessened the attention toward AD medication harshly though the aged people are vulnerable to 
both AD and COVID-19 [6]. The available therapeutic strategies are aimed at symptom – modifying targets 
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rather than preventing the neurons from damages [7]. For example, the drugs (donepezil, galantamin, 
memantine, rivastigmine) approved by the United States Food and Drug Administration (USFDA) can 
improve AD symptoms only through modulating brain neurotransmitter release [7]. Though AD symptoms 
appear in late 60s or later, initiation and progression of AD pathogenesis occurs at or during early 40s [8]. 
Thus, if protective measures could be taken at or before mid-ages of life, AD progression could be withheld, 
albeit, reduced [8]. The failure to achieve the ultimate goal in slowing AD progression might remain hidden 
into multiple causative factors encompassing oxidative stress (OS), hypercholesterolemia, hypertension, 
genetics, epigenetics as well as adaptive response to some stressors [1,5]. Thus, effective management of the 
co-existing factors of AD has been highly regarded in the most recent recommendation from the Alzheimer’s 
association [1,5]. Thus, time is up for considering AD ameliorating therapeutic approaches that would be easy 
to reach to the common mass of both the developing and developed nations. 
Hypercholesterolemia refers to the elevated level of cholesterol in the blood [9]. Hypercholesterolemia 
stems from the increased synthesis and/or decreased removal of endogenous cholesterol and also from the 
excessive supply of dietary cholesterol or cholesterol precursors [10]. Hypercholesterolemia plays pivotal role 
in the progression of AD [9-11]. Increased brain level of cholesterol has been found during AD progression 
[9-11]. The role of cholesterol in AD pathogenesis becomes clearer from the opposite relationship between 
plasma HDL-cholesterol level and dementia [9-12].  HDL is the main lipoprotein in the human brain and can 
slow down the in vitro aggregation of Aβ and subsequent toxicity [9-12]. Some studies have indicated 2-3 
times greater risk of late-age dementia and AD for those having mid-life hypercholesterolemia [9-12]. Thus, 
hypercholesterolemia stands as an early risk factor for AD [13-14]. Similarly, hypercholesterolemia is among 
the major modifiable risk factors of CVD [13-14]. Cholesterol lowering drugs, statins or 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been reported to lower the risk of death or 
cardiovascular events in patients with or without CVD as well as protective against the risk of developing AD 
[15-17]. Statins have been found effective in reducing the risk of AD from 60% even up to 74% [15-17]. 
Statins can directly withstand the production of Aβ and also facilitate their removal from the brain [15-17].  
The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on 
Cardiovascular Disease Prevention in Clinical Practice had suggested life-style and dietary modification as 
the first line and pharmacological intervention through utilization of lipid lowering drugs as the second line of 
treatment strategy against hypercholesterolemia [18]. Life style modification involves loss of weight, 
consumption of diet containing less cholesterol and higher saturated fatty acid, giving up of cigarette smoking 
and alcohol drinking, intake of unsaturated fatty acids such as DHA and regular physical exercise [18]. 
However, combination of both life style modification and pharmacological treatment sound better in real life 
[18]. 
Both edible and medicinal mushrooms lower blood total cholesterol (TC), very low density 
lipoproteins (VLDL) and low density lipoproteins (LDL) in rats [19-28]. Investigations involving the 
potentiality of mushrooms as the inhibitor of cholesterol biosynthetic key enzyme 3-hydroxy 3-methyl 
glutaryl co-enzyme A reductase (HMGCo-AR) have yielded promising outcome [28]. Ganoderma lucidum 
has been hailed for its immense medicinal values [19, 21-23]. Among them, its antioxidative, anticancer, 
antibiotic, antiviral, hepatoprotective and neuroprotective effects are most notable [19, 21-23]. Medicinal feat 
of G. lucidum could be attributed to its content of polysaccharides, polyphenols and triterpenes [23-25]. 
Despite vast expanse of research concerning G. lucidum, there is hardly any study addressing combined 
hypocholesterolemic and AD ameliorating effect of this mushroom, though both of these pathophysiologies 
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have some common links. Thus, the present study has been designed to elucidate the effect of G. lucidum on 
experimentally induced hypercholestorlemic and AD model animals.  
2. MATERIALS AND METHODS 
2.1. Preparation of hot water extract of G. lucidum 
Purchased from a local farm in Selangor, Malaysia, the fruiting bodies of G. lucidum were identified 
and authenticated by experts via DNA sequencing by Mushroom Research Centre, University of Malaya 
herbarium. A voucher specimen was deposited in the University of Malaya herbarium (KLU-M1233). 
Powdered fruiting bodies of G. lucidum were boiled in distilled water at the ratio of 1: 20 (w/v) for 45 
minutes. Cooling was followed by removal of the boiled mushrooms using Whatman No. 1 filter paper. Then, 
the hot water extracts (HWE) of G. lucidum were obtained using freeze-dryer (Labconco).  
2.2. Preparation of AD and HC model animals 
2.2.1. Animals, maintenance and dosage of treatment 
Forty eight wistar male rats (weight range 120 ± 5 gm) were divided into six groups: control (C),              
G. lucidum HWE fed control (CE), hypercholesterolemic (H), G. lucidum HWE fed hypercholesterolemic 
(HE), Alzheimer’s disease (A) and G. lucidum HWE fed Alzheimer’s disease (AE) each group containing 8 
rats. The extract fed groups (CE, HE and AE) received 200 mg/kbw G. lucidum HWE. Animals had been 
housed in a 12 hr day night cycle at 25±2°C temperature. All the experimental protocols had been approved 
by the ethical permission committee, University of Malaya Institutional Animal Care and Use Committee 
(UMIACUC) [Ethics reference no. ISB/25/04/2013/NA (R)]. 
2.2.2. Induction of hypercholesterolemia 
Hypercholesterolemia to the H rats was evoked by adding 1% cholesterol and 1% cholic acid (for 
intestinal better absorption of cholesterol) with the basal diet of the rats [23]. 
2.2.3. Preparation of AD model rats 
Alzheimer’s disease model rats (A) were prepared by infusing Aβ1-42 (ab120959, Abcam, USA) to the 
cerebral ventricles following the method of Abdullah et al. [29].  
2.3. AD studies 
2.3.1. Barnes maze study 
Memory and learning related behavioral performance of the rats was evaluated using Barnes maze. A 
Barnes maze made of stainless steel and having a diameter of 150 cm was used (Fig. 1). It contained 20 holes, 
each having a diameter of 10.5 cm. One of the holes contained the dark escape box. The maze top has been 
placed on a metal stand and elevated 100 cm above the floor. Intra- and inter-maze cues of different types 
such as colored paper-shapes (round, square and triangle) had been placed as the landmarks for cognition and 
spatial memory. The surface of the maze had been brightly illuminated using flush (120 W) light based on the 
principle that the rodents tend to hide in the dark corner as compared to the illuminated open center of a 
circular surface. In Barnes maze, spatial learning and memory is measured based on the rodents’ ability to 
learn and remember the location of the hidden escape box using the visual cues. After experimentation with 
each rat, the target hole and the whole maze was cleaned with 70% ethanol. All the sessions were recorded 
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using video camera (HDR CX130E, Sony, Japan) and Arcsoft showbiz software and the video files were 
tracked with the tracking software Kinovea. 
2.4. Sacrifice of the animals 
Twenty four hours following the last treatment and test, the rats were kept fasting overnight. Then, the 
rats were anesthesized with intra-peritoneal injection of sodium pentobarbital (35 mg/kbw) and sacrificed.   
2.5. Statistical analyses 
Conducting all the experiments in triplicate, data have been presented as mean±SEM. Using SPSS 
version 16, ANOVA was performed following least significance difference at 95% level. 
3. RESULTS AND DISCUSSION 
3.1. Hypocholesterolemic effect of G. lucidum HWE 
3.1.1. Effect of G. lucidum HWE on body weight change 
Gradual increase in body weight (ranging from 140 ± 5 g up to 280 ±2 g) of the rats of all the groups 
was noticed throughout the experimental period (Fig. 1). However, the hypercholesterolemic rats (H) gained 
the maximum weight and their rate of becoming weighty surpassed that of the others. Weight gain tendency of 
the normo-cholesterolemic rats was moderate and feeding of G. lucidum HWE resulted in decreased weight 
gain as time passed by. Similarly, G. lucidum HWE fed AD rats experienced relatively lower body weight 
growth than their non-fed counterparts. These findings indicate towards body weight lowering potencies of 
the G. lucidum HWE up on the experimental animals. 
 
 
Figure 1. Effect of G. lucidum HWE upon body weight change of the rats. 
Data are expressed as mean±SEM of triplicate measurements. Data were analyzed with one-way ANOVA and post-hoc Tukey’s  
HSD test (P≤0.05). Where, C = Control, CE = G. lucidum HWE fed control, H = hypercholesterolemic, HE = G. lucidum HWE  
fed hypercholesterolemic, A = AD model rats and AE = G. lucidum HWE fed AD rats, respectively (n=8 for every group). 
 
Current findings are in agreement with several others who reported a gradual increased body weight in 
the cholesterol fed rats [30]. As the present experimental animals were almost matured from their beginning 
of the experiment, decreased body weight gain of the G. lucidum HWE fed rats might occur due to decreased 
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fat (triacylglycerol) deposition, decreased cholesterol biosynthesis or increased lipolysis and/or the combined 
effect of all. 
3.1.2. Effect on plasma TG level 
Feeding of hypercholesterolemic diet to the rats resulted in their increased plasma TG levels (Table 1). 
The hypercholesterolemic (H) rats had 1.88 times higher plasma TG level compared to the controlled (C) rats 
indicating the increased atherogenic propensity of the H rats. Feeding of G. lucidum HWE lowered plasma 
TG level in both the control, hypercholesterolemic and AD rats. Plasma TG lowering effect of the G. lucidum 
HWE was in the order of controlled (20%) > hypercholesterolemic (16%) > AD (11%) rats (Table 1). TG 
lowering effect of G. lucidum HWE was statistically significant in each group compared to their respective 
controls (Table 1). Increased TG levels in the hypercholesterolemic rats might be due to the decreased 
clearance of TG owing to the lowered lipoprotein lipase (LPL) activity or due to increased deposition of     
LDL-C [31]. TG lowering effect of the HWE G. lucidum might be mediated through increased inhibition of 
the HMGR by the phenolics content of the HWE of G. lucidum [23, 28].  
 
Table 1. Lipid profile of the experimental animals. 


































































Data are expressed as mean±SEM of triplicate measurements each (n=8). Mean values containing different lower case superscripts are 
statistically significant at P≤0.05 level with one-way ANOVA and post-hoc Tukey’s HSD test of every triplicate data. Where, TG = 
triacylglycerol; TC = total cholesterol; HDL-C = high density lipoprotein-cholesterol; LDL-C = low density lipoprotein cholesterol;         
VLDL-C = very low density lipoprotein cholesterol; C = Control, CE = G. lucidum HWE fed control, H = hypercholesterolemic, HE =                 
G. lucidum HWE fed hypercholesterolemic, A = AD model rats and AE = G. lucidum HWE fed AD rats (n=8, in every group), respectively.  
 
3.1.3. Effect on plasma TC level 
Feeding of hypercholesterolemic diet to the rats resulted in 1.62 times increased plasma TC levels 
(Table 1). Later on, treating the rats with G. lucidum HWE lowered plasma TC level significantly (P≤0.05) in 
all the rat groups. TC lowering effect of G. lucidum might be mediated by competitive inhibition of HMG  
Co-A reductase, the rate limiting step of cholesterol biosynthesis, or through inhibition of 14α demethylase by 
the ganoderic acids or by impaired intestinal absorption by β-D glucan present in the G. lucidum HWE [24]. 
3.1.4. Effect on plasma HDL-C level 
In the present study, the hypercholesterolemic and AD rats had lowered plasma HDL levels compared 
to the normo-cholesterolemic controls (Table 1). Feeding of G. lucidum HWE increased plasma HDL-C levels 
significantly (P≤0.05) in all the rat groups. However, the rate of increasing was highest in the 
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normocholesterolemics and the increasing trend was C (27.5%) > H (22.80%) > A (20.20%) rats (Table 1). 
Lowered level of HDL-C in the hypercholesterolemic rats of the present study might be due to the accelerated 
clearance of apo A1 from the plasma following hypercholesterolemia in the H and A rats [32]. On the other 
hand, significantly increased (P≤0.05) plasma HDL-C level in the G. lucidum HWE fed rats indicates 
increased clearance of TC from the peripheral tissue to the liver for excretion that points towards CVD 
ameliorating effect of G. lucidum HWE.  
3.1.5. Effect on plasma LDL-C and VLDL-C level 
Plasma LDL-C level increased 1.92 times in the hypercholesterolemic and 1.42 times in the AD rats, 
compared to the respective controls (Table 1). Similarly, plasma VLDL-C level increased by 1.76 times in the 
H and by 1.65 times in the A rats. Increased levels of LDL-C and VLDL-C in the hypercholesterolemic rats 
might arise from their intake of hypercholesterolemic diet that might have downregulated the hepatic LDL 
receptors of the H rats [32]. Ganoderma lucidum HWE supplementation caused significant lowering effect 
upon plasma level of both LDL-C and VLDL-C in all the rat groups (Table 1). Ganoderma lucidum HWE 
caused significantly lowering effect upon the plasma LDL-C level of both H and AD rats as compared to the 
controlled. Ganoderma lucidum HWE mediated decreased cholesterol absorption and biosynthesis might 
cause decreased availability of hepatic cholesterol for lipo-protein biosynthesis in the extract fed rats (CE, 
HE, AE). As a consequence, decreased VLDL secretion in the plasma along with decreased conversion of 
VLDL into LDL may end into lowered plasma LDL level [32]. Mechanistically, G. lucidum HWE induced 
increased LDL receptor in the rat hepatocytes may contribute to the LDL lowering effect that resulted in 
lowered secretion of LDL in the rat plasma [32]. Increased clearance of LDL from the blood of the 
mushroom-fed rats may also have been involved [32].   
3.2. AD ameliorating effects of G. lucidum HWE 
3.2.1. Barnes maze study 
Compared with the respective controls, the G. lucidum HWE fed rats made less mistake in finding the 
escape box (Fig. 2). This observation corresponds towards enhanced memory and learning abilities of the              
G. lucidum HWE fed rats. To the best of our knowledge, ours is the first report concerning Barnes maze study 
of G. lucidum HWE fed rats and thus comparative discussion could not be furthered. Ganocomponents of 
different structure and function might have imparted AD ameliorating effect observed in this behavioral study 
[20-24]. 
3.2.2. Effect of G. lucidum HWE on memory and learning related markers 
3.2.2.1. BDNF 
Brain derived neurotrophic factor (BDNF), a neuroprotectin group of growth factor, is involved in 
neuronal survival and functioning. Its pivotal role in in non-neuronal cells such as in smooth muscle and 
endothelial cells have also been documented [34]. Though BDNF has been regarded as a pro-atherogenic 
factor, recent studies have reported its ameliorating effects on CVD [35]. Elevated BDNF levels have been 
reported to be associated with lowered CVD morbidity and mortality [35]. 
In the present study, we observed significantly reduced level of BDNF in the AD rats compared to 
those of the controls (Fig. 3). However, BDNF level increased in the G. lucidum HWE fed rats: in the HC rats, 
Rahman et al.   Ganoderma lucidum against hypercholesterolemia and Alzheimer’s disease 320 
 
European Journal of Biological Research 2020; 10(4): 314-325 
the level increased much than those of the AD rats. Thus, increased BDNF level in the G. lucidum HWE fed 
rats indicate both AD and hypercholesterolemia ameliorating effects. In this regard, our findings coincide with 
those of Kaess et al. [34]. Observed memory and learning related behavioral attainment of the G. lucidum 
HWE fed rats are also substantiated by this marker [35-38]. Tri-terpenoids and phenolics present in                         




Figure 2. Total errors of the rats in finding escape cage. 
Data are expressed as mean±SEM (n=8; each trial is the average of six sessions). Data were analyzed with one-way ANOVA and post-hoc 
Tukey’s HSD test (P≤0.05). Here, C = Control, CE = G. lucidum HWE fed control, A = AD model rats, AE = G. lucidum HWE fed AD 
rats, H=hypercholesterolemic and HE = G. lucidum HWE fed hypercholesterolemic rats, respectively. 
 
 
Figure 3. Effect of G. lucidum HWE on memory and learning related markers. 
Mean values containing different lower case superscripts are statistically significant at P≤0.05 level with one-way ANOVA  
and post-hoc Tukey’s HSD test (n=8). Here, BDNF = Brain derived neurotrophic factor, SNAP = Synaptosomal associated  
protein, PSD95 = Post-synaptic density protein 95 KD, TNFα = Tumor necrosis factor alpha, C = Control, CE = G. lucidum  
HWE fed control, H = hypercholesterolemic, HE = G. lucidum HWE fed hypercholesterolemic, A = AD model rats and  
AE = G. lucidum HWE fed AD rats, respectively. 
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3.2.2.2. SNAP 25 
Synaptosomal-associated protein 25 KD (SNAP 25), a pre-synaptic membrane protein plays important 
role in maintaining long-term potentiation (LTP) and working memory [40-41]. Reduced level of SNAP25 
had been reported in AD brains [40-41]. Similar trend was observed in the hippocampi of the AD rats in the 
present study (Fig. 3). Interestingly, G. lucidum HWE fed rats showed significantly (P ≤ 0.05) soared level of 
SNAP 25 in their hippocampi that might impart improved cognitive performance of the G. lucidum HWE fed 
rats. SNAP25 has also been implicated in elevating serum triacylglycerol level and weight increment [42]. 
Thus, the increased SNAP25 level in the HC rats might have been due to elevated expression of SNAP25 in 
those rats.  
3.2.2.3. PSD 95 
Post-synaptic density and maturation of the excitatory synapses are maintained by the post-synaptic 
density protein 95 KD (PSD95) [43]. Inverse relationship between Aβ and PSD95 level has been reported in 
the AD hippocampi [44]. In line with this, lowered level of PSD95 has been observed in the AD rats 
hippocampi, compared with those of the normal (Figure 3). There was an increment of PSD95 level in the             
G. lucidum HWE treated rats’ hippocampi that correspond to their improved memory and learning abilities 
(Fig. 3). Besides, level of PSD95 had been reported to be increased in hypercholesterolemic rats [45]. 
Elevated level of PSD95 in the HC rats of the present study coincide with the reported findings [45]. 
3.2.2.4. TNFα 
Tumor necrosis factor alpha (TNFα), a neurotoxin, acts as pro-AD signaling agent, promotes 
atherogenesis and disrupts lipid metabolism [46-48]. Increased level of TNFα in the AD and HC rats 
correspond towards disrupted cognitive performance and dyslipidemia of the respective rat groups (Fig. 3). 
These AD hallmarks have been ameliorated with G. lucidum HWE treatment that might be attributed towards 
its content of phenolics, triterpenoids and polysaccharides [19-23].  
3.2.2.5. VAchT 
Cholinergic neurotransmission is regulated by the vesicular acetylcholine transporter (VAchT) and its 
reduced level impairs cognitive performance, another hallmark of AD [49]. AD and HC rats of the present 
study showed lower level of VAchT while those of the G. lucidum HWE treated showed enhanced level (Fig. 
3). Thus, AD and HC rats had suffered from disrupted cholinergic neuronal activities while G. lucidum HWE 
treatment could ameliorate this disruption [50-51].  
4. CONCLUSIONS 
Infusion of soluble Aβ1-42 to the rat cerebral ventricles affected AD model rats’ memory and learning 
related behavioral tasks indicating the effectiveness of the current model of AD studies. Hypercholesterolemic 
model rats also showed poor performance in behavioral tests. Feeding of G. lucidum HWE to the AD and 
hypercholesterolemic rats improved their memory and learning abilities. Memory-related protein marker tests 
also indicate hypercholesterolemia and AD ameliorating effect of G. lucidum. Thus, G. lucidum could be 
regarded as an AD and hypercholesterolemia ameliorating agent. However, further study is needed for 
formulating therapeutic dosage.  
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